Phase 1 N=60 Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose
ETEC Diarrhea
Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea
Phase 2 N=475 Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh
Escherichia Coli Diarrhea
Primary: Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum Severity — 15; 14; 15; 15 Participants
N/A N=28 Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A
Healthy Volunteer
Primary: Number of Participants With Safety- Solicited Symptoms Related to Challenge Administration — 0; 0; 3; 2 Participants
Phase 2 N=60 Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
Diarrhea
Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events
Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
Phase 2 N=120 Traveler's Diarrhea (TD) Automated Process
Prevention of Travelers' Diarrhea
Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer
N/A N=60 Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
Phase 1 N=50 Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
Diarrhea
Primary: Number of Participants With Solicited Adverse Events — 2; 5; 9; 9 Participants
N/A N=700 Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients
Urinary Tract Infection · Infection Due to ESBL Bacteria · Environmental Contamination of ESBL
Primary: Treatment Failure — 23; 101 Treatment success
Phase 1 N=57 Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea
Escherichia Coli Infection
Primary: Safety - Occurrence of Adverse Events — 7; 21; 19; 20 Number of Adverse Events
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Phase 3 N=182 ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
Clostridium Difficile Infection
Primary: Recurrence of CDI up to 8 Weeks — 11; 37 Participants — p=<0.001
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 1 N=53 Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122
Shigella Infection · Enterotoxigenic Escherichia Coli Infection
Primary: Participants Experiencing Fever, Diarrhea, or Dysentery; Solicited Local Adverse Events; Solicited Systemic Adverse Events; and Clinical Safety Laboratory Adverse Events…
Phase 4 N=88 Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis
Diarrhea
Primary: Duration of Diarrhea — 2; 2 days — p=0.43
Phase 2 N=9 A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization
Antibiotic Resistant Strain
Primary: Percentage of Participants With VRE Decolonization — 1; 1 Participants
Phase 3 N=971 Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis
Gastroenteritis
Primary: Number of Participants With Modified Vesikari Scale Score >=9 — 55; 60 Participants — p=0.83
N/A N=18 Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis
Eosinophilic Gastroenteritis
Primary: Percent of Participants in Complete Histologic Remission — 100 percentage of participants
N/A N=147 Trial of Rifaximin in the Treatment of Tropical Enteropathy
Tropical Enteropathy
Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc
Phase 4 N=15 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants
Phase 2 N=600 Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch
Diarrhea
Primary: Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs…
Phase 3 N=263 ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
Clostridioides Difficile Infection
Primary: Cohort 1: Recurrence of CDI and Sustained Clinical Response — 4; 25 Participants
Phase 2 N=108 Phase 2 Shigella Vaccine and Challenge
Immunisation · Shigella Infection
Primary: The Proportion of Participants With Shigellosis Following Challenge With Shigella Sonnei 53G Through Day 63 in the Pooled Group of Participants Receiving Two Doses of…
Phase 2 N=71 A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults
Dysentery, Bacillary
Primary: Percentage of Subjects With at Least One Episode of Shigellosis According to the Protocol Primary Case Definition — 46.9; 42.9 Percentage of subjects — p=0.4266
N/A N=1,545 Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study
Infectious Gastroenteritis
Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants
Phase 2 N=10 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Clostridium Difficile Infection
Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants
Phase 2 N=47 Cholera Anti-Secretory Treatment Trial
Cholera
Primary: Diarrheal Stool Output Rate — 25.42; 32.57 mL/hour — p=0.2254
Phase 2 N=160 LT Vaccine Patch Self-Administration Study
Prevention of Travelers' Diarrhea
Primary: GMTs After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch. — 362; 442; 1974; 2896 geometric…
Phase 1 N=56 Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain
Healthy
Primary: Number of Participants With Shigellosis — 0; 2; 1; 4 Participants